Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven B Chinn

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 18, 2020
CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapyBenjamin S Rosen, Joel R Wilkie, Yilun Sun, et al.
Head & Neck|March 18, 2023
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancerJoshua D Smith, Megan L Ludwig, Apurva D Bhangale, et al.
Science (New York, N.Y.)|May 7, 2026
Intermetallic nanoassemblies potentiate systemic STING activationXingwu Zhou, Xiang Ling, Xiaoqi Sun, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 3, 2019
Assessment of Intraoperative Nerve Monitoring Parameters Associated With Facial Nerve Outcome in Parotidectomy for Benign DiseaseCatherine T Haring, Susan E Ellsperman, Bruce M Edwards, et al.
The Journal of Molecular Diagnostics : JMD|May 7, 2026
Validation of MyHPVscore: a high-performance HPV ctDNA lab developed testJordan Currie, Heather Walline, Colleen G Hochfelder, et al.
Oral Oncology|November 2, 2022
Prognostic value of CD103<sup>+</sup> tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinomaJoshua D Smith, Emily L Bellile, Susan E Ellsperman, et al.
Nature Communications|December 28, 2025
BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunityWang Gong, Hülya F Taner, Yuesong Wu, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 18, 2020
CT and FDG-PET radiologic biomarkers in p16+ oropharyngeal squamous cell carcinoma patients treated with definitive chemoradiotherapyBenjamin S Rosen, Joel R Wilkie, Yilun Sun, et al.
Head & Neck|March 18, 2023
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancerJoshua D Smith, Megan L Ludwig, Apurva D Bhangale, et al.
Science (New York, N.Y.)|May 7, 2026
Intermetallic nanoassemblies potentiate systemic STING activationXingwu Zhou, Xiang Ling, Xiaoqi Sun, et al.
JAMA Otolaryngology-- Head & Neck Surgery|May 3, 2019
Assessment of Intraoperative Nerve Monitoring Parameters Associated With Facial Nerve Outcome in Parotidectomy for Benign DiseaseCatherine T Haring, Susan E Ellsperman, Bruce M Edwards, et al.
The Journal of Molecular Diagnostics : JMD|May 7, 2026
Validation of MyHPVscore: a high-performance HPV ctDNA lab developed testJordan Currie, Heather Walline, Colleen G Hochfelder, et al.
Oral Oncology|November 2, 2022
Prognostic value of CD103<sup>+</sup> tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinomaJoshua D Smith, Emily L Bellile, Susan E Ellsperman, et al.
Nature Communications|December 28, 2025
BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunityWang Gong, Hülya F Taner, Yuesong Wu, et al.
Pageof 11